MOTS-c

II. What is this compound?

The discovery reads like a plot twist. For decades, mitochondrial DNA was treated as a parts list: a few protein recipes plus assembly instructions for the cell's machines. Then researchers found an open reading frame tucked inside the 12S rRNA gene — coding for something no one expected there: a functional peptide.

They named it MOTS-c, short for Mitochondrial Open Reading Frame of the 12S rRNA-c. The molecule itself is modest — 16 amino acids, about 2174.5 Da, one of the mitochondrial-derived peptides. The striking part is where it comes from: most regulatory molecules trace back to nuclear DNA, but MOTS-c is read directly off the genome that runs the cell's energy supply.

That origin places it squarely at the intersection of energy metabolism and health — and it's why researchers synthesize it for preclinical studies of metabolism and aging. How a 16-amino-acid peptide manages that is exactly what the mechanism work set out to answer.

III. How it works

MOTS-c doesn't act like a single tool; it acts like a hand on the cell's master energy switch: AMPK, the AMP-activated protein kinase central to improving insulin sensitivity. Studies indicate that boosting AMPK activity may improve glucose uptake and lipid metabolism — the two levers most relevant to metabolic disorders [PMID: 25565208, PMID: 27060479].

Two supporting mechanisms round out the picture. Research suggests MOTS-c inhibits the folate cycle and de novo purine biosynthesis, shifting cells toward altered energy states and metabolic reprogramming [1] PMID: 25565208 . It's the quieter half of the story: a metabolic reroute rather than a switch flip.

Research also suggests the peptide promotes the nuclear translocation of signaling molecules that regulate metabolic genes — the mitochondria sending instructions to the nucleus about energy homeostasis [2] PMID: 27060479 . Here's the twist: its half-life in plasma is short — minutes — yet cellular effects persist, the signature of a peptide that reconfigures signaling rather than passing through. Which raises the next question: what does the switch actually produce?

• Activation of AMPK signaling pathway improving insulin sensitivity
  PMID 25565208PMID 27060479
• Inhibition of folate cycle and de novo purine biosynthesis
  PMID 25565208
• Nuclear translocation and transcriptional regulation of metabolic genes
  PMID 27060479

IV. Research Findings

For anyone tracking blood sugar, body composition, or how well they're aging, the preclinical picture hits all three. Research suggests MOTS-c may improve metabolic health through better insulin sensitivity and glucose metabolism, with potentially better outcomes in obesity and related disorders [PMID: 25565208, PMID: 27060479].

Fat loss appears in the record too: studies indicate MOTS-c may support fat loss, feeding straight back into those metabolic benefits [3] PMID: 25565208 . Then there's the headline — preclinical findings point to possible anti-aging properties, though almost all that evidence comes from animal models rather than human trials [4] PMID: 27060479 .

That qualifier calibrates excitement instead of killing it: it tells you exactly where the science stands and where human research still needs to run. It also sets up the practical question — what doses have researchers actually used?

• metabolic-health preclinical
  PMID 25565208PMID 27060479
• anti-aging preclinical
  PMID 27060479
• fat-loss preclinical
  PMID 25565208

V. Dosage Context Explained

In experimental settings, researchers have given MOTS-c at 5 to 15 mg/kg/day via subcutaneous injection, primarily in mouse models of obesity and aging [5] PMID: 25565208 . Those figures describe what produced measurable effects under controlled rodent conditions — nothing more.

Human dosing regimens remain unestablished, and higher-level clinical evidence would be needed before any human-relevant guidelines could exist. Until then, every dose number attached to MOTS-c stays a research reference point — which turns the safety file, thin as it is, into the next logical question.

• Administration Routes

  subcutaneous

  Range

  5–15 mg/kg/day

  animal models (mouse obesity and aging studies)

  PMID 25565208

VI. Side Effects: Research Context

The preclinical safety file is unusually quiet: no side effects have been documented in animal research so far, suggesting a favorable profile in those models. One theoretical flag keeps researchers attentive — active malignancies — because a peptide that reprograms cellular metabolism is exactly the kind of lever that demands caution there.

Both the quiet file and the theoretical flag stay provisional until human evidence accumulates. That's the honest state of the science: a clean record you can't rely on yet — and a reminder that this is a research compound, not a treatment.

• none documented in preclinical models

VII. Frequently Asked Questions